Physician profile
David A Beck
NPI 1073626339
$1,916.99
in general payments reported to CMS, 2019-2025
29 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $133 · 2021: $501 · 2022: $499 · 2023: $150 · 2024: $155 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.13 | 2019-2025 | Qulipta, Ubrelvy |
| Amgen INC. | $141.33 | 2019-2025 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $124.19 | 2019-2021 | |
| Novo Nordisk INC | $117.86 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $75.35 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.02 | 2022 | |
| Merck Sharp & Dohme LLC | $70.09 | 2019-2020 | |
| Daiichi Sankyo INC. | $68.02 | 2022-2025 | Injectafer |
| Pfizer INC. | $58.99 | 2023-2025 | |
| Lilly USA, LLC | $58.31 | 2021-2025 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $53.89 | 2021 | |
| Allergan, INC. | $50.66 | 2019-2020 | |
| Hologic Sales and Service, LLC | $50.30 | 2021-2025 | Thinprep 2000 Processor |
| Astellas Pharma US INC | $47.20 | 2025 | Veozah |
| Baxter Healthcare | $38.29 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $35.48 | 2024 | Monoferric |
| Eisai INC. | $33.11 | 2021-2022 | |
| Organon LLC | $28.93 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $27.88 | 2023 | Myfembree |
| Shield Therapeutics INC | $26.71 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $22.04 | 2025 | |
| Horizon Therapeutics Plc | $21.08 | 2021 | |
| Currax Pharmaceuticals LLC | $16.64 | 2024 | Contrave |
| Myovant Sciences INC. | $16.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.27 | 2019 | |
| Axsome Therapeutics, INC. | $15.19 | 2022 | |
| Biocryst US Sales Co., LLC | $14.00 | 2022 | |
| Roche Diagnostics Corporation | $11.37 | 2020 | |
| Coopersurgical, INC. | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.